Tackling risk reduction in ASCVD: Sharing international experience

Tackling risk reduction in ASCVD: A clinical case  

Tackling risk reduction in ASCVD
Media formats available:
  • Overview

    Reducing ASCVD risk is a challenge, especially in patients with residual risk despite various therapies. This series of 3 videos provides valuable information to help you with this, thereby focusing on the omega-3 FA icosapent ethyl, which contains purified EPA.

    This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.

  • Program Highlights

    This educational program consists of three presentations on risk reduction in ASCVD with icosapent ethyl.

    Mechanistic clues to understanding the benefits of icosapent ethyl -Matthew Budoff, MD - Los Angeles, CA, USA

    • Mechanistic studies on plaque characteristics in patients receiving EPA can be insightful to understand the CV risk reductions seen in clinical trials. Prof. Budoff gives an overview of effects of EPA on multiple plaque components.

    Tackling risk reduction in ASCVD: A clinical case - Lawrence Leiter, MD - Toronto, ON, Canada 

    • Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl. 

    Addressing late-breaking data on triglycerides, fibrates and omega-3 FAs - Peter Libby, MD (Boston, MA, USA), Gabriel Steg, MD (Paris, France), and Kausik Ray, MD (London, UK) 

    • An international expert panel discusses the results of trials with pemafibrate and EPA. What do these findings mean for management of patients in clinical practice? 
  • Instructions

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate

    For questions regarding this activity, please contact us at

  • Learning Objectives

    • Describe the study results seen with EPA and the combination of EPA and DHA
    • Explain the mechanisms behind the effect of EPA on plaque progression
    • Describe the place of icosapent ethyl in ASCVD risk management
    • Recall the main results of the PROMINENT and RESPECT-EPA trials
    • Name at least 2 ways to overcome clinical inertia with regard to reducing ASCVD risk
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with ASCVD.

  • Accreditation and Credit Designation Statements

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Commercial Support

    Funding for this educational program was provided by an unrestricted educational grant from Amarin. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free